LDB17 Antibody

What is LDB17 and why is it significant in endocytosis research?

LDB17 (Low Dye Binding 17) is a novel conserved component of the endocytic machinery, first identified through systematic quantitative analysis of yeast endocytosis. Its significance lies in its role as a regulator of normal coat dynamics and actin assembly during endocytosis. LDB17 is recruited to cortical actin patches before actin polymerization begins, suggesting it functions as a critical link between coat formation and the initiation of actin polymerization in the endocytic process . This protein contains a PTHR13357 domain also found in the mammalian protein SPIN90, which has been implicated in clathrin-mediated endocytosis, highlighting evolutionary conservation of this pathway .

How does LDB17 interact with other endocytic proteins?

LDB17 interacts with multiple proteins through its C-terminal proline-rich domain (PRD). Co-immunoprecipitation studies have confirmed that LDB17 binds to the yeast syndapin homologue Bzz1 in a PRD-dependent manner . Additionally, yeast two-hybrid analysis has identified interactions between LDB17's PRD and the SH3 domains from proteins including Sla1, Lsb3, and Lsb4 . The interaction with Sla1 appears particularly important for LDB17 function, as loss of Sla1 reduces the lifetime of LDB17 at the cell surface from 9 seconds to 5 seconds, suggesting Sla1 binds the LDB17 PRD to enhance its membrane association at endocytic sites .

What temporal role does LDB17 play in the endocytic process?

Kymograph analysis has revealed that LDB17 is maximally recruited after assembly of the late coat components and immediately before the recruitment of the myosin module. Specifically, LDB17 joins preexisting Sla1 patches just before the onset of Sla1 inward movement and Myo5 recruitment . Myo5 patches appear approximately 3 seconds after LDB17 patches, while LDB17 dissociates from the membrane about 4 seconds before Abp1 disassembly . This temporal positioning supports LDB17's hypothesized role in linking coat formation to actin polymerization, a critical step in endocytic vesicle formation.

What validation methods are essential for confirming LDB17 antibody specificity?

Multiple validation approaches should be employed to confirm antibody specificity:

• Western blot analysis using wild-type lysates compared against ldb17Δ mutant samples

• Immunoprecipitation followed by mass spectrometry to confirm target identity

• Immunofluorescence microscopy comparing staining patterns between wild-type and knockout samples

• Testing for cross-reactivity with related proteins, especially those containing similar domains like PRDs

• Pre-absorption tests with purified recombinant LDB17 protein

The ability to recognize native LDB17 in its cellular context is particularly important given its transient recruitment to endocytic sites and its interactions with multiple binding partners .

How can researchers distinguish between phosphorylated and non-phosphorylated forms of LDB17 using antibodies?

Distinguishing between phosphorylated and non-phosphorylated forms requires phospho-specific antibodies developed against known or predicted phosphorylation sites in LDB17. The approach should include:

• Bioinformatic analysis to identify potential phosphorylation sites

• Generation of phospho-specific antibodies using synthetic phosphopeptides

• Validation using samples treated with phosphatase inhibitors versus phosphatase-treated samples

• Comparative immunoprecipitation studies before and after treatments that affect endocytic dynamics

This differentiation is methodologically important as phosphorylation state may regulate LDB17's recruitment timing and interactions with binding partners during the endocytic process.

What are the optimal fixation and permeabilization methods for LDB17 immunofluorescence staining?

Optimal fixation and permeabilization protocols for LDB17 immunofluorescence should preserve both protein localization and epitope accessibility. Based on similar endocytic proteins:

For permeabilization, a gentle approach using 0.1-0.2% Triton X-100 for 5-10 minutes is recommended, as harsh detergents might disrupt the delicate cortical actin patches where LDB17 localizes . For particularly challenging epitopes, antigen retrieval using citrate buffer (pH 6.0) at 95°C for 10 minutes may improve antibody accessibility while maintaining the integrity of endocytic structures.

How can LDB17 antibodies be used to track temporal dynamics during endocytosis?

To track temporal dynamics of LDB17 during endocytosis using antibodies:

• Use pulse-chase labeling with distinct secondary antibodies at different time points

• Employ proximity ligation assays (PLA) to detect LDB17 interactions with time-specific endocytic markers

• Combine with live-cell imaging by microinjecting fluorescently labeled non-disruptive LDB17 antibodies

• Apply super-resolution microscopy techniques (STORM, PALM) with appropriate antibody conjugates

These approaches can complement the established timeline where LDB17 joins preexisting Sla1 patches just before Sla1 inward movement, with Myo5 patches appearing approximately 3 seconds after LDB17 . This methodological framework allows researchers to map precise recruitment and dissociation kinetics relative to other endocytic components.

What considerations are important when using LDB17 antibodies in co-immunoprecipitation experiments?

When using LDB17 antibodies for co-immunoprecipitation:

• Select lysis buffers that preserve PRD-dependent interactions (avoid harsh ionic detergents)

• Consider crosslinking approaches for capturing transient interactions

• Include control immunoprecipitations with non-specific antibodies of the same isotype

• Validate findings with reciprocal co-IPs using antibodies against identified binding partners

• Determine optimal antibody concentrations empirically for each experimental condition

These methodological considerations are particularly important given LDB17's known interactions with multiple proteins including Bzz1, Sla1, Lsb3, and Lsb4 through its PRD . The transient nature of these interactions during the endocytic process necessitates careful experimental design to accurately capture physiologically relevant protein complexes.

How can researchers use LDB17 antibodies to study the effects of actin dynamics on endocytosis?

LDB17 antibodies can be instrumental in studying actin dynamics during endocytosis through several methodological approaches:

• Dual immunofluorescence labeling with LDB17 antibodies and actin markers before and after treatment with actin-disrupting drugs like latrunculin A (LatA)

• Quantitative image analysis measuring co-localization coefficients between LDB17 and actin under various experimental conditions

• Immunoelectron microscopy to visualize LDB17 localization relative to actin structures at nanometer resolution

• Live-cell super-resolution microscopy with microinjected labeled antibodies combined with fluorescent actin probes

These approaches leverage the observation that LDB17's membrane localization is dramatically enhanced when treated with LatA, indicating actin is not required for its membrane recruitment . This methodological framework enables dissection of the sequential recruitment of endocytic proteins and their relationship to actin polymerization.

What methodologies can resolve conflicting data between LDB17 localization in fixed versus live-cell experiments?

To resolve discrepancies between fixed and live-cell experiments:

• Direct comparative analysis using correlative light and electron microscopy (CLEM)

• Sequential imaging of the same cells before fixation and after antibody staining

• Quantitative dwell time measurements comparing antibody-labeled structures with fluorescent protein fusions

• Super-resolution microscopy to determine if spatial resolution limitations contribute to apparent differences

This methodological approach is particularly relevant given LDB17's transient nature and the observation that it forms faint puncta at the cell surface with partial overlap with other endocytic proteins like Sla1, Myo5, and Abp1 . The short lifetime of LDB17 at the cell surface (approximately 9 seconds in wild-type cells) makes capturing its true dynamics particularly challenging .

How can researchers use LDB17 antibodies to investigate the relationship between endocytosis defects and disease models?

Investigating endocytosis defects in disease models using LDB17 antibodies requires:

• Comparative immunohistochemistry between normal and diseased tissues to assess LDB17 expression and localization

• Co-localization studies with disease-specific markers and other endocytic proteins

• Functional assays measuring cargo uptake efficiency in conjunction with LDB17 antibody staining

• Phosphorylation-specific antibody analysis to determine if disease states alter LDB17 post-translational modifications

This is particularly relevant given that mammalian homologs of LDB17, such as SPIN90, have been implicated in clathrin-mediated endocytosis in fibroblasts . The evolutionary conservation of this protein family (most organisms contain a single PTHR13357 family member) suggests potential relevance to human disease processes involving endocytic dysfunction .

How can researchers overcome low signal issues when detecting endogenous LDB17?

Low signal detection for endogenous LDB17 presents a common challenge due to its low abundance, as noted in proteomic studies . Methodological approaches to overcome this include:

• Signal amplification techniques such as tyramide signal amplification (TSA) or rolling circle amplification

• Optimized antibody concentration determined through systematic titration experiments

• Enhanced detection systems using high-sensitivity fluorophores or quantum dots

• Reduced background strategies including careful blocking optimization and use of monovalent Fab fragments

• Antibody pooling using multiple validated antibodies targeting different LDB17 epitopes

These approaches address the challenge observed in the scientific literature where LDB17-GFP was "difficult to visualize due to its low abundance" . Researchers should empirically determine the optimal approach for their specific experimental system.

What strategies can minimize artifacts when studying LDB17's interactions with the actin cytoskeleton?

To minimize artifacts when studying LDB17-actin interactions:

• Optimized fixation timing to capture transient associations

• Gentle permeabilization protocols that preserve actin structures

• Sequential antibody application starting with actin labeling followed by LDB17 detection

• Controlled temperature conditions throughout the immunostaining process

• Validation with multiple actin visualization methods (phalloidin, actin antibodies, LifeAct)

This methodological attention is crucial given that actin dynamics are critical for LDB17 function, and aberrant actin distribution has been observed in ldb17 mutants, similar to the large actin clumps found in sla1 mutants .

How can researchers accurately quantify changes in LDB17 localization patterns?

Accurate quantification of LDB17 localization changes requires:

These quantitative approaches should be adapted to address specific research questions, such as measuring the observed reduction in LDB17 lifetime at the cell surface from 9 seconds to 5 seconds when Sla1 is absent . Rigorous statistical analysis and appropriate controls are essential for meaningful interpretation of quantitative localization data.

How might LDB17 antibodies be used to explore evolutionary conservation of endocytic machinery?

LDB17 antibodies offer powerful tools for exploring evolutionary conservation through:

• Cross-species immunoblotting to detect homologous proteins in diverse organisms

• Comparative immunoprecipitation to identify conserved and divergent interaction partners

• Functional rescue experiments using antibody depletion followed by complementation with homologs

• Epitope mapping to identify structurally conserved regions across species barriers

This approach is particularly relevant given that LDB17 contains a PTHR13357 domain also found in the mammalian protein SPIN90, and most organisms contain a single PTHR13357 family member . These evolutionary insights could reveal fundamental mechanisms of endocytosis conserved throughout eukaryotic evolution.

What methodological advances could improve simultaneous detection of multiple endocytic proteins including LDB17?

Advancing simultaneous detection of multiple endocytic proteins requires:

• Multiplexed antibody labeling using distinct species, isotypes, or recombinant antibody fragments

• Sequential epitope detection with antibody stripping and reprobing protocols

• Mass cytometry adaptation for single-cell protein complex analysis

• Proximity-based detection methods like proximity ligation assays or FRET-based antibody pairs

These approaches could help map the complete interaction network surrounding LDB17, building on known interactions with proteins like Sla1, Bzz1, Lsb3, and Lsb4 , while potentially discovering new binding partners or regulatory relationships.

How can researchers integrate LDB17 antibody-based findings with emerging technologies in endocytosis research?

Integration of antibody-based findings with emerging technologies could include:

• CRISPR-based endogenous tagging validated against antibody detection patterns

• Lattice light-sheet microscopy combined with antibody-based pulse-chase approaches

• Cryo-electron tomography with immunogold labeling to map LDB17 within the 3D endocytic structure

• Optogenetic manipulation of LDB17 recruitment combined with antibody-based tracking

These integrated approaches would build upon fundamental discoveries about LDB17's role in linking coat formation to actin polymerization while addressing remaining questions about the precise molecular mechanisms involved in this critical transition during endocytosis.